Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Onderzoek om meer te weten te komen over de veiligheid van Fazirsiran en of het mensen kan helpen met alfa-1-antitrypsine-leverziekte met milde leverlittekens (fibrose)

6 november 2026 bijgewerkt door: Takeda

Een gerandomiseerde, dubbelblinde, placebogecontroleerde fase 3-studie om de veiligheid en werkzaamheid van Fazirsiran te evalueren bij de behandeling van alfa-1-antitrypsinedeficiëntie-geassocieerde leverziekte met METAVIR-stadium F1-fibrose

The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver.

People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study.

After their last clinic visits, participants will have two choices:

  1. They can complete this study and return to the clinic 3 and 6 months later so the study doctors can check for side effects; OR
  2. If they meet the rules, they can join another study (called extension or continuation study), in which they will receive fazirsiran every 3 months and will continue to have health checks.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

50

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Antwerp, België, 2650
        • Werving
        • UZ Antwerpen
        • Hoofdonderzoeker:
          • Sven Francque
        • Contact:
      • Leuven, België, 3000
        • Werving
        • UZ Leuven
        • Hoofdonderzoeker:
          • Jef Verbeek
        • Contact:
    • Ontario
      • Toronto, Ontario, Canada, M5T 3A9
        • Werving
        • Inspiration Research Limited
        • Hoofdonderzoeker:
          • Kenneth Chapman
        • Contact:
          • Site Contact
          • Telefoonnummer: (416) 944-9602
      • Aachen, Duitsland, 52074
        • Werving
        • Universitätsklinikum der RWTH Aachen
        • Hoofdonderzoeker:
          • Pavel Strnad
        • Contact:
      • Berlin, Duitsland, 13353
        • Werving
        • Charité - Campus Virchow-Klinikum
        • Contact:
        • Hoofdonderzoeker:
          • Frank Tacke
      • Hanover, Duitsland, 30625
        • Werving
        • Hannover Medical School
        • Hoofdonderzoeker:
          • Heiner Wedemeyer
        • Contact:
          • Site Contact
          • Telefoonnummer: +495115322730
      • Tübingen, Duitsland, 72076
        • Werving
        • Universitätsklinikum Tübingen
        • Hoofdonderzoeker:
          • Christoph Berg
        • Contact:
          • Site Contact
          • Telefoonnummer: +4970712977661
      • Lyon, Frankrijk, 69317
        • Werving
        • Hôpital de La Croix Rousse
        • Contact:
        • Hoofdonderzoeker:
          • Teresa Antonini
      • Rennes, Frankrijk, 35000
        • Werving
        • Hopital PONTCHAILLOU CHU de Rennes
        • Contact:
        • Hoofdonderzoeker:
          • Edouard Bardou-Jacquet
      • Val-de-Marne, Frankrijk, 94800
        • Werving
        • Hôpital Paul Brousse
        • Contact:
        • Hoofdonderzoeker:
          • Audrey Coilly
      • Pavia, Italië, 27100
        • Werving
        • Fondazione IRCCS Policlinico San Matteo
        • Hoofdonderzoeker:
          • Angelo Corsico
        • Contact:
          • Site Contact
          • Telefoonnummer: +390382503777
      • Graz, Oostenrijk, 8036
        • Werving
        • LKH-Universitätsklinikum Graz
        • Contact:
        • Hoofdonderzoeker:
          • Martin Wagner
      • Klagenfurt, Oostenrijk, 9020
        • Werving
        • KABEG - Klinikum Klagenfurt Am Wörthersee
        • Hoofdonderzoeker:
          • Markus Peck-Radosavljevic
      • Mysłowice, Polen, 41-400
        • Ingetrokken
        • ID Clinic Arkadiusz Pisula
      • Braga, Portugal, 4710-243
        • Werving
        • CCA Hospital Braga
        • Hoofdonderzoeker:
          • Carla Rolanda
      • Funchal, Portugal, 9000-168
        • Werving
        • Hospital Dr. Nélio Mendonça
        • Hoofdonderzoeker:
          • Vitor Pereira
        • Contact:
          • Site Contact
          • Telefoonnummer: (351) 291-7056 x00
      • Porto, Portugal, 4099-001
        • Werving
        • Centro Hospitalar de Universitário de Santo António E.P.E
        • Contact:
          • Site Contact
          • Telefoonnummer: +351918000000
        • Hoofdonderzoeker:
          • Luís Maia
      • Seville, Spanje, 41018
        • Werving
        • Hospital Universitario Virgen del Rocio - PPDS
        • Contact:
        • Hoofdonderzoeker:
          • Manuel Romero Gómez
      • London, Verenigd Koninkrijk, SE5 9RS
        • Werving
        • King's College Hospital
        • Hoofdonderzoeker:
          • Aftab Ala
        • Contact:
          • Site Contact
          • Telefoonnummer: +442032993506
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85013-4224
        • Werving
        • St Joseph's Hospital and Medical Center
        • Hoofdonderzoeker:
          • Justin Reynolds
        • Contact:
          • Site Contact
          • Telefoonnummer: 602-274-7195
      • Phoenix, Arizona, Verenigde Staten, 85054-4502
        • Werving
        • Mayo Clinic - PPDS
        • Hoofdonderzoeker:
          • Hugo Vargas
        • Contact:
      • Tucson, Arizona, Verenigde Staten, 85724-0001
        • Werving
        • University of Arizona Thomas D. Boyer Liver Institute
        • Contact:
        • Hoofdonderzoeker:
          • Geoffrey Block
    • California
      • La Jolla, California, Verenigde Staten, 92037-1337
        • Werving
        • University of California San Diego
        • Hoofdonderzoeker:
          • Rohit Loomba
        • Contact:
      • Los Angeles, California, Verenigde Staten, 90095-3075
        • Werving
        • UCLA Pulmonary and Critical Care
        • Hoofdonderzoeker:
          • Igor Barjaktarevic
        • Contact:
          • Site Contact
          • Telefoonnummer: 310-825-8061
      • San Francisco, California, Verenigde Staten, 94143-2203
        • Werving
        • University of California Benioff Children's Hospital
        • Hoofdonderzoeker:
          • Philip Rosenthal
        • Contact:
    • Colorado
      • Colorado Springs, Colorado, Verenigde Staten, 80907
        • Werving
        • Peak Gastroenterology Associates
        • Hoofdonderzoeker:
          • Bhaktasharan Patel
        • Contact:
          • Site Contact
          • Telefoonnummer: 719-636-1201
    • Florida
      • Miami, Florida, Verenigde Staten, 33136
        • Werving
        • Schiff Center for Liver Diseases/University of Miami
        • Hoofdonderzoeker:
          • Eugene Schiff
        • Contact:
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202-2266
        • Werving
        • Indiana University School of Medicine-Indianapolis
        • Hoofdonderzoeker:
          • Raj Vuppalanchi
        • Contact:
          • Site Contact
          • Telefoonnummer: 317-278-4607
    • Iowa
      • Iowa City, Iowa, Verenigde Staten, 52242-1009
        • Werving
        • University Of Iowa Hospitals And Clinics
        • Hoofdonderzoeker:
          • Tomohiro Tanaka
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02118-2335
        • Werving
        • Boston Medical Center
        • Hoofdonderzoeker:
          • Arpan Mohanty
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • Werving
        • University of Michigan Hospital - 1500 E Medical Center Dr
        • Hoofdonderzoeker:
          • Robert Fontana
        • Contact:
          • Site Contact
          • Telefoonnummer: 734-232-3741
      • Novi, Michigan, Verenigde Staten, 48377-3600
        • Werving
        • Henry Ford Health System
        • Hoofdonderzoeker:
          • Stuart Gordon
        • Contact:
    • Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Werving
        • Mayo Clinic PPDS
        • Hoofdonderzoeker:
          • Harmeet Malhi
        • Contact:
          • Site Contact
          • Telefoonnummer: 507-284-0141
    • New York
      • New York, New York, Verenigde Staten, 10016-6402
        • Werving
        • NYU Langone Medical Center
        • Hoofdonderzoeker:
          • Viviana Figueroa Diaz
        • Contact:
      • New York, New York, Verenigde Staten, 10032-3722
        • Werving
        • Columbia University Irving Medical Center
        • Hoofdonderzoeker:
          • Monica Goldklang
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44106-1716
        • Werving
        • University Hospitals Cleveland Medical Center
        • Hoofdonderzoeker:
          • Seth Sclair
        • Contact:
          • Site Contact
          • Telefoonnummer: 216-983-0879
    • Pennsylvania
      • Hershey, Pennsylvania, Verenigde Staten, 17033-2360
        • Werving
        • Penn State Health Milton S. Hershey Medical Center
        • Hoofdonderzoeker:
          • Timothy Craig
        • Contact:
    • Texas
      • San Antonio, Texas, Verenigde Staten, 78215
        • Werving
        • Texas Liver Institute American Research Corporation
        • Hoofdonderzoeker:
          • Eric Lawitz
        • Contact:
    • Virginia
      • Newport, Virginia, Verenigde Staten, 23602-4414
        • Werving
        • Bon Secours St. Mary's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Mitchell Schiffman
      • Huddinge, Zweden, 14186
        • Werving
        • Karolinska Universitetssjukhuset Huddinge
        • Contact:
          • Site Contact
          • Telefoonnummer: +46858580000
        • Hoofdonderzoeker:
          • Staffan Wahlin
      • Bern, Zwitserland, 3010
        • Werving
        • Universitätsspital Bern
        • Hoofdonderzoeker:
          • Guido Stirnimann
        • Contact:
          • Site Contact
          • Telefoonnummer: +41442663568

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • In the opinion of the investigator, the participant is capable of understanding and fully complying with the protocol requirements and adhering to the protocol schedule.
  • The participant is able to read, understand, and complete the study questionnaires electronically per the investigator's judgment.
  • The participant signs and dates a written Informed Consent Form (ICF). Any required privacy authorization should also be signed before the initiation of any study procedures.
  • The participant, of any sex, is aged 18 to 75 years, inclusive.
  • The participant must have a diagnosis of the protease inhibitor Z mutation (PiZZ) genotype AATD. A diagnosis of PiZZ from source-verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.
  • The participant's liver biopsy core samples collected as per protocol requirements.
  • The participant has evidence of METAVIR stage F1 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading from a previous biopsy conducted within 1 year before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.
  • The participant has a pulmonary status that meets the protocol requirements.
  • It must be confirmed that the participant does not have hepatocellular carcinoma (HCC).
  • Any participant who is taking statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or beta-1 selective adrenergic receptor inhibitors must have been receiving a stable dose of these medications for at least 8 weeks before randomization. All attempts are to be made for the participant to continue the same dose of the medication for the duration of study participation.
  • An adult participant must have a body mass index (BMI) greater than or equal to (>=) 18 kilogram per meter square (kg/m^2).
  • The participant has a 12-lead electrocardiogram at screening that, in the opinion of the investigator, has no abnormalities that could compromise the participant's safety in this study.
  • The participant is a nonsmoker.
  • If the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone less than or equal to [<=10] milligrams per day [mg/d] or its equivalent), the doses of the participant's medications must have remained unchanged for >=4 weeks before screening.
  • The participant must have suitable venous access for blood sampling.
  • A person of childbearing potential (POCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 before dosing.
  • The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study and for 6 months after the last dose of study medication. The participant must not donate sperm for at least 6 months after the last dose of study medication.

Exclusion criteria:

  • The participant has evidence of >= F2 fibrosis based on liver biopsy during the screening period.
  • The participant has a history of liver decompensating events.
  • The participant has a history of varices based on a previous esophagogastroduodenoscopy.
  • The participant has portal vein thrombosis.
  • The participant has undergone a prior trans-jugular portosystemic shunt procedure.
  • The participant has evidence of other forms of chronic liver diseases.
  • The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of metastatic disease and disease-free interval greater than (>) 1 year may be enrolled. Individual cases may be discussed with the medical monitor for guidance.
  • The participant has an abnormal finding of clinical relevance at the screening evaluation and before administration of the first dose of study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results.
  • The participant has any laboratory abnormalities at screening and before the first dose of the study drug that meet protocol parameters.
  • The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.
  • The participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months prior to screening, unless, in the opinion of the investigator, the participant has achieved clinical recovery with pulmonary function returned to baseline. Individual cases may be discussed with the medical monitor for guidance.
  • The participant has a history of frequent pulmonary exacerbations (>=2 moderate or severe exacerbations within 52 weeks before screening).
  • The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be rescreened after the clinical resolution of an exacerbation).
  • The participant is receiving long-term, around-the-clock oxygen supplementation or supplemental oxygen with continuous positive airway pressure (CPAP) or bilevel positive airway pressure for acute respiratory failure. The following conditions are allowable for the participant to enter screening: short-term use of oxygen supplementation (example, for the management of acute chronic obstructive pulmonary disease [COPD] exacerbation) or CPAP for obstructive sleep apnea.
  • The participant has human immunodeficiency virus (HIV) infection as shown by the presence of anti-HIV antibody (seropositive).
  • The participant is seropositive for hepatitis B virus (HBV surface antigen positive and/or HBV core antibody positive without HBV surface antibody at screening) or hepatitis C virus (HCV) (detectable HCV Ribonucleic Acid [RNA] at screening). Cured HCV (positive antibody test without detectable HCV RNA for at least 6 months after treatment) is acceptable.
  • The participant has unstable, poorly controlled, or severe hypertension. Participants may be rescreened once their blood pressure (BP) is successfully controlled.
  • The participant has a history of ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if they participate in the study, in the opinion of the investigator. Examples of significant ECG abnormalities include: torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long QT syndrome or new ST-segment elevation or depression or a new Q wave on ECG.
  • The participant has symptomatic heart failure (per New York Heart Association guidelines), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction less than [<] 20 percent [%]), transient ischemic attack, or cerebrovascular accident within 6 months before screening.
  • The participant has a history of major surgery within 12 weeks of screening (or longer, at the discretion of the investigator).
  • The participant has a history of more than moderate alcohol consumption within 12 months before the screening visit.
  • The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.
  • The participant has previously been treated with fazirsiran or any other RNA interference (RNAi) for alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).
  • The participant has a history of hypersensitivity or allergies with any associated excipients of fazirsiran.
  • The participant has received an investigational agent or device within 30 days, or 5 half-lives, whichever is longer, before the dosing of study medication or is currently participating in an investigational study involving a therapeutic intervention.
  • The participant has donated >=500 milliliter (mL) of blood within 1 month of the administration of study treatment.
  • The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk. The participant has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurologic, psychiatric, gastrointestinal (GI), systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
  • The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 6 months before screening, or is taking chronic anticoagulants.
  • This participant is unable to return for all scheduled study visits.
  • The participant has symptomatic confirmed coronavirus disease 2019 (COVID-19) that, in the opinion of the investigator, does not resolve during screening; however, enrollment may be temporarily delayed at the discretion of the investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation. Individual cases may be discussed with the medical monitor for guidance.
  • The participant is a study site employee involved in the conduct of this study, an immediate family member (example, spouse, parent, child, sibling), is in a dependent relationship with study site employee who is involved in the conduct of this study or may consent under duress.
  • The participant takes or is required to take excluded medications.
  • The participant is pregnant or breastfeeding or intending to become pregnant before participating in this study, during the study, or within 6 months after last dose of the study drug; or the participant is intending to donate ova during such time period.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Fazirsiran 200 mg

Participants will receive fazirsiran 200 milligrams (mg), injection, subcutaneously on Day 1, at Week 4 and then every 12 weeks (Q12W) for up to Week 100.

Fazirsiran will be injected subcutaneously.

Andere namen:
  • TAK-999
  • ARO-AAT
  • ADS-001
Placebo-vergelijker: Placebo

Participants will receive fazirsiran matching placebo injection, subcutaneously on Day 1, at Week 4 and Q12W for up to Week 100.

Fazirsiran matching placebo.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Tijdsspanne: From start of study drug administration up to end of study (EOS) (Week 124)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study intervention. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, suspected transmission of any infectious agent, an important medical event. AEs and SAEs including any pulmonary AEs or SAEs indicative of worsening pulmonary condition (example, pulmonary exacerbation, respiratory infection, significant pulmonary function test decline) will be reported.

From start of study drug administration up to end of study (EOS) (Week 124)
Number of Participants With Clinically Significant Change From Baseline in Pulmonary Function Parameters
Tijdsspanne: From start of study drug administration up to EOS (Week 124)

Standard pulmonary function parameters will be used to study lung function. Clinical significance of pulmonary function parameters will be determined at the investigator's discretion.

From start of study drug administration up to EOS (Week 124)
Change From Baseline in Whole Lung 15th Percentile Density as Measured by Computed Tomography (CT) Lung Densitometry
Tijdsspanne: Baseline up to Week 100

Change from baseline in whole lung 15th percentile density as measured by CT lung densitometry will be assessed.

Baseline up to Week 100
Number of Participants With Clinically Significant Changes in Vital Signs
Tijdsspanne: From start of study drug administration up to EOS (Week 124)

Vital signs include body temperature, respiratory rate, blood pressure (systolic and diastolic), pulse (beats per minute) and pulse oximetry. Clinical significance of vital signs will be determined at the investigator's discretion.

From start of study drug administration up to EOS (Week 124)
Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Tijdsspanne: From start of study drug administration up to EOS (Week 124)

12-lead ECG will be evaluated. Any clinically significant change in ECG assessments will be determined at the investigator's discretion.

From start of study drug administration up to EOS (Week 124)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Tijdsspanne: From start of study drug administration up to EOS (Week 124)

Laboratory parameters assessments include hematology, biochemistry including liver tests, coagulation, and urinalysis. Clinical significance of laboratory parameters will be determined at the investigator's discretion.

From start of study drug administration up to EOS (Week 124)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change From Baseline in Serum Z-AAT Protein Over Time to Week 106
Tijdsspanne: Baseline up to Week 106

Change From Baseline in Serum Z-AAT Protein will be assessed.

Baseline up to Week 106
Percent Change From Baseline in Intrahepatic Liver Z-AAT Protein at Week 106
Tijdsspanne: Baseline up to Week 106

Percent change from baseline in intrahepatic liver Z-AAT protein will be assessed.

Baseline up to Week 106
Change From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 106
Tijdsspanne: Baseline up to Week 106

Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining in liver biopsy will be assessed.

Baseline up to Week 106
Number of Participants with No Change or Decrease From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by PAS+D Staining at Week 106
Tijdsspanne: Baseline up to Week 106

Number of participants with no change or decrease from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining will be reported.

Baseline up to Week 106
Change From Baseline in Intrahepatic Portal Inflammation Score in Liver Biopsy at Week 106
Tijdsspanne: Baseline up to Week 106

Change in portal inflammation score in liver biopsy is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation.

Baseline up to Week 106
Number of Participants with No Change or Decrease From Baseline in Intrahepatic Portal Inflammation Score at Week 106
Tijdsspanne: Baseline up to Week 106

No Change or decrease in portal inflammation score is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation. Number of Participants with no change or decrease from baseline in intrahepatic portal inflammation score will be reported.

Baseline up to Week 106
Number of Participants With No Change or Decrease From Baseline in Histologic Fibrosis Score (Meta-analysis of Histological Data in Viral Hepatitis [METAVIR] Staging) at Week 106
Tijdsspanne: Baseline up to Week 106

No change or decrease in histologic fibrosis (METAVIR staging) will be assessed using a fibrosis score of F0-F4, where higher scores mean a worse result. Number of participants with no change or decrease from baseline in histologic fibrosis score (by [METAVIR] staging) at Week 106 will be reported.

Baseline up to Week 106
Change From Baseline in Vibration-Controlled Transient Elastography (VCTE)-Derived Liver Stiffness
Tijdsspanne: Baseline up to Week 106

Change from baseline in VCTE-derived liver stiffness will be assessed.

Baseline up to Week 106
Change From Baseline in Markers of Liver Injury
Tijdsspanne: Baseline up to Week 106

Change from baseline in marker (alanine aminotransferase [ALT], aspartate aminotransferase [AST], glutamyl transferase [GGT]) of liver injury will be assessed.

Baseline up to Week 106

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Study Director, Takeda

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 maart 2024

Primaire voltooiing (Geschat)

26 augustus 2028

Studie voltooiing (Geschat)

26 augustus 2028

Studieregistratiedata

Eerst ingediend

1 december 2023

Eerst ingediend dat voldeed aan de QC-criteria

1 december 2023

Eerst geplaatst (Werkelijk)

11 december 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

6 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD-toegangscriteria voor delen

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF
  • MVO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren